Clinical Trials

A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010).


Study ID
MK-7902-010-01

NCT Number
NCT04199104 (Click on the NCT number for more information about the trial)

Research Study Number
20192891

Principle Investigator
Dr. Alter, Robert

Phase
III

Sponsor
Merck & Co.


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now